Nutra Pharma’s wholly-owned medical devices subsidiary, Designer Diagnostics, is currently planning to undergo third party validation for its nontuberculous mycobacterium (NTM) diagnostic test kits at Tuberculosis Research Institute, National Jewish Medical and Research Center, in Denver, Colorado. The company plans to apply for FDA approval upon successful completion of this clinical trial.
Rik Deitsch, chairman and CEO of Nutra Pharma, said: “Combining our newly licensed intellectual property with our current test kit technology will allow our subsidiary, Designer Diagnostics, to attempt to successfully launch a cost-effective solution to help identify the environmental sources of NTM infections.”